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INTRODUCTION 
          Osteoarthritis is the most common rheumatologic disease of old 
age. It is a slowly progressive degenerative disease according for major 
restriction of activities of daily living in the elderly. Symptoms of 
osteoarthritis include pain, stiffness and restriction of joint movement and 
deformity of joint. 
          Osteoarthritis usually affects knee, hip, hands, Spine rarely ankle. 
Radiographic evidence of OA outnumbers the clinically evident 
osteoarthritis. 
          There is no definite cure for OA. Wide variety treatment measures 
include weight reduction, modification of activities to reduce stress and 
load on the joint. Pharmacotherapy, such as analgesics, judicious, use of 
NSAIDS or intraarticular steroid injection. 
          Total joint replacement is the treatment of choice but could not be 
done in all patients.  
          Although osteoarthritis is a non inflammatory disease, some 
inflammatory process occurs in the joint causing pain. 
          Recent investigation focus on various biomarkers to assess 
osteoarthritis severity and to classify disease progression, the aim of our 
study is to consider one such marker of inflammation hsCRP as a tool of 
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disease severity, x-ray grading of knee joint is studied in comparison with 
hsCRP levels and patient symptoms. 
While treating osteoarthritis patient the treating physician should. 
• Create an awareness of the disease and educate the patient to 
change the activities of daily living for secondary prevention of 
complication. 
• To inform the patient about various treatment options available 
individual risk and benefits of each modality. 
• To attain optimal quality of life with appropriate available 
measures 
• To provide adequate rehabilitation measures for selected patients.  
          Our study design is cross sectional study designed to assess the 
correlation between severity with its symptoms. X-ray treatment and 
inflammatory marks. ie hsCRP  
 
 
 
 
 
 
  
 
AIMS  
AND  
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AIMS AND OBJECTIVES 
 
• To study serum hsCRP levels in sample of osteoarthritic patient. 
 
• To assess hsCRP level in correlation with clinical symptoms and 
radiological signs. 
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REVIEW OF LITERATURE 
Osteoarthritis is chronic degenerative disease of joint, characterised 
by erosion of articular cartilage, bone hypertrophy at the margins, 
subchondral sclerosis and varying biochemical and morphological 
alteration of synovial membrane and joint capsule.   
OA is a leading cause of disability, increase in health costs and 
impaired quality of life. 
OA is a disease process affecting entire joint structure including 
cartilage, synovial membranes, subchondral bone, ligaments and 
periarticular muscles. 
 OA is considered as a group of overlapping disorders of varies 
aetiologies including (genetic) systemic and local factors (biochemical 
and biomechanical) that ultimately converge to produce a condition with 
definable morphologic and clinical outcome. 
OA may be classified as primary or secondary. Primary OA has no 
identifiable aetiology or predisposing cause and is the most common 
type. Secondary OA, has identifiable cause but pathologically  
indistinguishable  from primary OA.Metabolic condition ( calcium crystal 
deposition, hemochromatosis, acromegaly) anatomic factors ( leg length 
5 
 
inequality, congenital  hip dislocation), traumatic or sequelae  of 
inflammatory disorders  ankylosing spondylitis , septic arthritis. 
ETIOLOGIES OF SECONDARY OSTEOARTHRITIS 
Metabolic 
Crystal – associated arthritis  
Acromegaly  
Ochronosis  
Hemochromatosis  
Wilson’s diseases  
Hyperparathyroidism 
Ehlers-Danlos  
Gaucher’s diseases  
Diabetes  
Mechanical/ Local Factors 
Slipped capital Femoral epiphysis  
Epiphyseal dysplasia  
Legg-calve-perthes disease  
Congenital dislocation  
Femoroacetabular impingement  
Congenital hip dysplasia  
Limb length inequality  
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Hypermobility syndromes  
Avascular necrosis  
Traumatic  
Joint trauma e.g., ACLtear  
Fracture through joint  
Prior joint surgery e.g., meniscectomy    
Charcot joint  
Inflammatory  
Rheumatoid arthritis or other inflammatory arthritis 
Crystalline arthropathy (gout) 
History of septic arthritis  
 
EPIDEMIOLOGY  
Osteoarthritis is common in women than men. 45% of women over 
the age of 65 have symptoms of Osteoarthritis, However radiological 
evidence found in 70% over the age of 65 years. 
OA was estimated to the 10th  leading cause of non fatal burden in 
the world in 1990, now it has progressed to 4th leading cause. 
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PREVALENCE 
OA is not reversible hence prevalence of OA increases with the 
age. Population prevalence shows that Asian females are more prone for 
OA of the knee but not for the hip. OA of the hip occurs more common in 
European than Asian Indians. 
Prevalence in developing countries is similar to that of developed 
countries. 
The burden will be greater in developing countries like India where 
life expectancy is improving. 
One study shows occupation such as miners, dock workers, jobs 
involving high knee bending demands and farmers are at increased risk of 
OA knee.  
Farming also increases the risk of OA hip. 
OA hip and OA knee are most important from the view of public 
health based on their prevalence and associated disability. 
Mortality: OA is not a life threatening disease but mortality may 
occur from drugs such as NSAIDS leading to risk of renal failure. 
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INCIDENCE OF SYMPTOMATIC OSTEOARTHRITIS 
 
ETIOLOGIC FACTORS 
AGE:   
Most strongly correlated risk factors of OA1,2  more than 80% of 
person older than 70 yrs of age. 
• OA incidence increases progressively with age at all joints. 
• Age related structural change in joint cartilage includes fraying 
softening and thinning of articular surface and increased apoptosis 
of chondroctes. 
• Radiological changes appear before disease symptoms occur and 
also progresses as patient age increases 3. 
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JOINT LOCATION 
 OA is more common in weight bearing hip and knee joints4, occurs 
rarely in ankle joint. 
OA also occurs in hand joints including thumb interphalangeal 
joints, spine, shoulders, elbow and ankle are usually not involved.  
OBESITY 
• Obesity is important risk factor for OA of knee5,6,7, to some extent 
also a risk factor for osteoarthritis of  hip. 
• Obesity increases the force at weight bearing joints. 
• Obesity causes change in posture, gait and decrease physical 
activity contributing to altered joint biomechanics8. 
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• Obese patient exhibit varus deformities9 resulting in increased joint 
reactive forces in medial compartment, accelerating   degenerative 
process. 
• Obesity increases adipose tissue which produces inflammatory 
leptin, adiponectin. resistin, IL-1,IL-6 and TNF10,11 which have role 
in OA. 
GENETIC PREDISPOSITION 
• OA has higher concordance between monozygotic twins. 
• Inherited forms of OA caused by mutation in genes encoding 
collagen. 2, 4, 5 and 6 as well as cartilage oligomeric matrix 
protein (COMP12,13. 
• Vitamin D receptor also play a role in bone mineral density, there 
by genetic abnormalities in vitamin D receptors may cause 
osteoarthritis. 
• IL-1genes are important in coding cartilage formation. 
• Chromosome 2q14 may have the susceptible genes for OA several 
studies showed. 
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JOINT MALALIGNMENT AND TRAUMA 
• Joint malalignment and trauma causes rapid development of OA. 
• May also start slow process resulting in symptomatic OA years 
later.  
• May cause reduced blood supply to the peri articular region. 
• Altered joint geometry interferes with nutrition of cartilage or alter 
load distribution both may cause altered biochemical composition 
of cartilage15, 16. 
• Joint incongruence such as malreduced intraarticular fractures, 
developmental dysplasia of hip, recurrent dislocation of patella 
leads to early OA onset. 
• Repetitive high impact sports strongly associated with joint injury 
and increases risk of OA in lower limb17. 
• Regular exercise maintains good articular structure and metabolic 
function. 
• Articular cartilage is vulnerable to repetitive impact loading18, 
excess loads cause micro fractures causing callus formation and 
remodelling resulting in new bone that is stiffer and acts as less 
effective shock absorber predisposes to cartilage degeneration. 
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GENDER 
• Women are twice likely at risk of developing OA than men. 
• Before the age of 50 years women have lower prevalence of OA 
than men but after age of 50 years, women have higher prevalence 
of OA19, possibly due to oestrogen deficiency. 
• Women have many number of joints involved compared to men. 
• Oestrogen functional receptors are present in articular 
chondrocytes20.  
• Oestrogen replacement therapy in postmenopausal women have 
shown decreased risk of knee and hip OA21. 
• A prospective study showed when incident and progressive 
radiographic knee OA were combined current ERT users had 60% 
less risk of knee OA. 
CHANGES IN OSTEOARTHRITIS 
Before discussing changes in osteoarthritis shortly review of 
anatomy of knee. 
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ANATOMY OF THE KNEE 
 
 
 
 
 
          The knee is a complex hinge joint with tibio-femoral and patella-
femoral components. 
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          It has synovial capsule that extends under the quadriceps (the 
suprapatellar pouch) reaching   cm above the superior edge of the patella. 
The joint is largely subcutaneous, allowing easy palpation of the patellar 
tendon, tibial plateau margin and femoral condyles. The knee depends on 
its muscular and ligamentous structures for stability.. 
          The hamstring muscles flex the knee. Extension requires the 
quadriceps muscles, quadriceps tendon patella, patellar tendon and tibial 
tuberosity. Any disruption of this ‘extensor apparatus’ prevents straight-
leg raising or produces an extensor lag (a difference between active and 
passive ranges of extension). 
          The medial and lateral collateral ligament resist valgus and varus 
stress respectively. The anterior cruciate ligament prevents anterior 
subluxation of the tibia on the femur, and the posterior cruciate ligament 
resists posterior translation. The media and lateral menisci are crescentic 
fibrocartilaginous structures that lie between the tibial plateaus and the 
femoral condyles. 
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MORPHOLOGIC CHANGES; 
Early OA  
Articular cartilage surface becomes roughened and irregular, 
superficial clefts within cartilage appear. 
 Cartilage surface is fibrillated and small cracks  appear  matrix 
swelling , chondrocyte proliferation or limited amount of apoptosis may 
be evident. 
Advanced OA 
Articular cartilage surface is more irregular and superficial cleft 
extend into middle zone of cartilage. 
 Portion of superficial zone may be missing  
 Clefts deepens, surface irregularities increase and articular 
cartilage finally ulcerate and exposes underlying bone. 
 Joint articulates on exposed bone causes eburnation and bone 
thickening. 
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EARLY REPARATIVE, PROLIFERATIVE AND 
HYPERTROPHIC CHANGES: 
• Increase in number of chondrocytes in the form of clones and 
clusters22 is an attempt to self repair of damaged cartilage. 
• Chondrocytes are quiescent neither committing to proliferation nor 
to hypertrophic differentiation.  
• In early osteoarthritis chondrocytes proliferate and express higher 
level of matrix protein such as aggre can and type II23 collagen as 
well as stem cell markers24 and markers of hypertrophic changes. 
• Chondrocytes contribute to OA pathogenesis and progresses 
through releasing matrix degrading enzymes, growth factors and 
inflammation cytokines25. 
 
Osteoarthritic cartilage has surface irregularities, with clefts 
and cloning of chondrocytes. 
 
Osteoarthritis Normal 
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OSTEOPHYTE FORMATION 
• Osteophytes are newly formed fibrocartilage and bone formed in 
periphery margins of joints between cartilage and periosteum. 
• Osteophytes are believed to arise by chondrogenic differentiation 
of progenitor cells commonly from periosteum26. Osteophytes can 
contribute to stability of joints27. TGF-BETA28, BMP’S29, IGF30, 
Fibroblast growth factor are the factors promoting chondrogenic 
stem cell differentiation. 
• Relation between osteophyte formation and repair response is 
evident by animal models of OA in which osteophyte formation is 
evident as early as 3 days after injury. 
• During OA progression osteophytes limit joint movement and 
become painful. 
HYPOCELLULARITY 
• Normal adult cartilage has density between 24000/mm3 in the 
surface zone and 8000/mm3 in the deep zone. 
• Ageing cartilage has decreased cell number. 
• Cartilage has decreased cell synthesis function. 
• Cell death may occur via necrosis or apoptosis31. 
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• Inhibition of apoptosis by interfering with caspase activation is 
being investigated for preventing secondary OA. 
ALTERATION IN CARTILAGE MATRIX METABOLISM 
BIOCHEMICAL CHANGES  
• In early OA, cartilage water content increases causes tissue 
swelling and altering biomechanical functions. 
• In advanced OA, type 1 collagen concentration with in ECM 
increases, proteoglycan concentration decreases32, keratam 
sulphate concentration reduced, ratio of chondroitin -4-sulfate to 
chondroitin -6-sulfate increases. All is promotes immature cartilage 
production33. 
• Calcium crystals are found in cartilage of elderly and crystal 
arthropathy may coexist with OA34. 
• High levels of pyrophosphate correlates with joint damage. 
• Hemosiderin , copper, homogenitisic acid  polymers, monosodium 
urate crystals, calcium pyrophosphate dehydrate are examples of 
precipitating factors  in the development of OA. 
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METABOLIC CHANGES 
• Early OA activates chondrocytes which produce cartilage of 
inferior quality. 
ANABOLIC FACTORS (TRANSFORMING GROWTH FACTOR- 
Β, BONE MORPHOGENETIC PROTEINS) AND CARTILAGE 
REPAIR. 
•  TGF-beta is essential for formation and maintenance of cartilage. 
• TGF-beta functional interference can lead to OA in animal models. 
• TGF-beta affects cartilage homeostasis at different levels 
 
• Enhances stem cell chondrogenesis. 
• Also increases anticatabolic factors such as TIMPs and PAI-1 
• Attenuates the cellular response to inflammatory cytokines IL-1β and 
TNF. 
• BMP’s are related to TGF-beta structurally, but activate different 
receptors and intra cellular signalling molecules function similar to 
that.  
• Impaired BMP signalling affects OA susceptibility particularly BMP 
protein. 
• BMP 7 is found to be decreased in osteoarthritic cartilage and 
supplementation of BMP 7 can reduce arthritis in animals. 
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PICTORIAL REPRESENTATION OF  
PATHOGENESIS OF OA 
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CATABOLIC FACTORS AND CARTILAGE DEGRADATION 
• IL-1 and  TNF stimulate synthesis and secretion of many proteases 
and MMPs  
• MMPs cause proteolysis and cartilage remodelling 
• Enzymes stimulated by IL-1 and TNF are collagenase ,stromelysin, 
gelatinase, aggrecanase and tissue plasminogen activator 
• TPA converts plasminogen to plasmin that can activate latent 
cartilage degrading enzymes. 
• Cartilage integrity is maintained by balance between anabolic and 
catabolic factors 
BONE ABNORMALITIES 
i. Osteophyte formation  
• It is bony proliferation at the join margin in the floor of 
cartilage lesions. These are responsible for pain and restriction 
of join movement.  
• Osteophyte results from penetration of blood vessels into the 
degenerating cartilage. 
• Subchondral bon cyst are created by entry of synovial fluid 
through defects in cartilage. 
• Immobilization and steroids decrease size of Osteophytes. 
 
23 
 
ii. Subchondral bone sclerosis 
• Remodelling and hardening of subchondral bone occurs in 
osteoarthritis known as subchondral sclerosis. 
• It may be evident radiologically before loss of cartilage. 
 
iii. Bone marrow lesion. 
• It is detected by MRI are associated with OA. 
• May contribute to pain felt by the patient. 
• Its presence is predictive of disease progression development 
of cartilage defects and degradation and the need for joint 
replacement. 
MORPHOLOGICAL CHANGES  
 
1-Subchondral bone sclerosis, 2-Subchondral cyst, 3- Damaged cartilage. 
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INFLAMMATORY MOLECULES PRODUCED BY ARTICULAR 
CARTILAGE CYTOKINES AND CHEMOKINES 
• Established osteoarthritis has increased inflammatory cytokines.IL-
1β and TNF produced by articular chondrocytes 
• IL-1 and TNF induce chondrocytes and synovial cells to produce 
other inflammatory mediators like IL-6 ,IL-8, Nitric oxide and 
prostaglandin E  
• IL-1R antagonist have been studied and  shown to retard  OA 
progression in animals35. 
PROTEINASES 
Promote cartilage proteolysis through induction of proteases in 
particular matrix metallo proteinases   
Two family of protease (MMPs) are  
• Collagenase that breakdown type II collagen  MMP (1,8,13,28) 
and proteoglycans 
• Aggrecanase which mediate aggrecan degradation in 
cartilage36,37. 
• These two are expressed in OA cartilage at the site of lesion 
suggesting they have a role in ECM degradation. 
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NITRIC OXIDE  
• Produced by Inducible nitric oxide synthase. 
• Over production of nitric oxide by chondrocytes in response to 
cytokines IL-1 and TNF leads to cartilage destruction.  
• Cause articular cartilage degradation by inhibition of collagen 
and proteoglycan synthesis38. 
• And metalloproteinase activation39. 
• Increased susceptibility to injury by other oxidants (H2O2)40. 
• Apoptosis38. 
TGF-beta 
• TGF beta down regulates proteoglycans MMP1 and MMP13  
• TGF beta also acts on IL-1 and TNF-receptors on 
chondrocytes41. 
• TGF beta 2 suppress cleavage of type 11 collagen by 
collagenases 
HYALURONIC ACID 
• Hyaluronic acid can be detected in synovial fluid and serum of 
OA patients. 
• Hyaluronic acid is produced by synovium and in OA its 
production is increased. 
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• It provides lubrication for joint mobility  
PROSTAGLANDINS 
• Inducible COX-2 is expressed largely in OA chondrocytes and 
produce PGE2. 
• COX-2 inhibitions by NSAIDS prevents IL-1 mediated 
proteoglycans degradation 
F-SPONDIN 
• New mediator in OA cartilage is a neuronal ECM glycoprotein 
regulating cartilage degradation through TGF-beta and PGE2 
pathway 
ALTERATION IN SYNOVIAL TISSUE 
• Synovial inflammation and effusion are key features of OA 
pathophysiology 
• Some degree of synovitis has been observed in early OA. 
• Clinical symptoms and signs such as joint swelling and 
effusion, stiffness, pain reflect synovial inflammation 
• Synovial histology shows synovial hypertrophy and hyperplasia 
• Synovial inflammation is confined to areas adjacent to 
pathologically damaged cartilage and bone. 
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• Activated synovium release proteinase and cytokines 
destructing cartilage42. 
 
GRADING OF SYNOVIAL INFLAMMATION 
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PATHOPHYSIOLOGY OF OA 
Biomechanical factors  
Genetic  Extrinsic  
 
Altered metabolism  
Synovium Cartilage  Bone  
 
Inflammation 
Pain 
 
 
 
 
 
 
 
 
Future iNOS inhibitors IL-1 
antagonists MMP inhibitors  
Structural 
Damage 
Loss of Function  
ACETA,NSAIDs Intra-
articular steroids 
Viscosupplementation  
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BIOMARKERS OF OA 
COMP, cartilage intermediate layer protein (CILP), cartilage link 
protein matrilin and minor collagen and hyaluronic acid are synthesized 
and degraded in OA in excess levels. 
• In healthy cartilage this molecules have relatively slow turn over.-
These markers of cartilage matrix synthesis and degradation can be 
used as biomarkers of OA 
• Biomarkers of OA can be used to find  
o Burden of disease 
o Investigative markers  
o Prognostic markers 
o Efficacy and effectiveness of intervention 
o Diagnostic 
Examples of burden of disease and prognosis includes serum COMP,  
SERUM HA, AND URINARY CXT II 
• One study of patients with OA  knee compared MRI findings 
with level of serum HA ,osteocalcin , cartilage  glycoprotein 
39,COMP,and urine c-telopeptide of type collagen. Findings 
suggested one time measurement of HA or short term increase 
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in CTX II would identify patient at greater risk for OA 
progression44. 
CRP 
• OA is not considered as inflammatory disease but it definitely 
involves inflammatory process and it provides promise for 
biomarkers 
• Elevated levels of CRP appear to be predictive of radiographic 
progression of long term knee OA. 
• In a study of 1025 women, higher CRP levels are associated 
with statistically significant increase in both prevalent and 
incident OA and greater knee severity 
• Bilateral OA knee patient has comparatively higher CRP levels 
than unilateral OA 
• Body mass index should be taken into account for CRP levels45. 
• CRP are modestly but significantly elevated in OA early knee 
OA and Predictive of disease progression. 
COMP  
• COMP is a non-collagenous ECM protein synthesized by 
cartilage and synovium is abundant in articular cartilage46,47,48,49. 
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• COMP levels helpful in assessing presence and progression of 
OA  
• Synovial fluid COMP levels elevated in patients with knee 
injury ligaments or meniscal injury. 
• Serum COMP levels are higher in patients with rapidly 
progressing joint damage 
HYALURONIC ACID 
• HA is a cartilage degradation marker and can be detected in 
serum and synovial fluid50. 
• HA levels reflect activity of synovium , but proteoglycan levels 
reflect turnover of cartilage. 
• Higher serum HA levels have been correlated with number of 
joints involved and degree of clinical severity. 
• Serum HA levels also serve as predictor of OA disease 
progression. 
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BIO MARKERS IN OSTEOARTHRITIS 
 
15-HETE, 15-hydroxy eicosatetraenoic acid; hsCRP, highly 
sensitive C-reactive protein; IL, interleukin; IL-1Ra, interleukin-1 
receptor antagonist; PBL, peripheral blood leukocytes; PGE2, 
prostaglandin E2; TNF, tumor necrosis factor . 
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CLINICAL FEATURES OF OA 
ACR radiologic and clinical criteria for OA 
KNEE: CLINICAL 
1) Knee pain for most days of prior month 
2) Crepitus with active joint motion  
3) Morning stiffness lasting < 30 min 
4) Bony enlargement of the knee on examination 
5) Age ≥ 38 yrs 
Diagnosis requires 1+2+4 or 1+2+3+5 or 1+4+5 
Knee clinical and Radiographic 
1) Knee pain for most days of prior month 
2) Osteophytes at joint margin  
3) Synovial fluid typical of osteoarthritis  
4) Age ≥ 40 yrs 
5) Morning stiffness lasting < 30 min 
6) Crepitus with active joint motion 
Diagnosis requires 1+2+3 or 1+2+4 or 1+3+4 
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CLINICAL FEATURES: 
General symptoms and signs 
 OA affects knees, hands, feet, hip and spine. 
 OA patients describe pain in joint that is worse with activities 
with limited morning stiffness <30 minutes. 
 Pain and stiffness occurs after rest called “gelling” 
phenomenon. 
 Affected joints in OA have bony enlargement and on 
examination have crepitation 
 
KNEE OA: 
 Insidious onset of pain with gelling and limited range of 
movements. 
 OA patient describe pain and limitation with walking transferring 
as from seated to standing. 
 Stiffness, loose bodies and meniscal lesions may contribute to 
“locking” sensation. 
 Pain over medial or lateral joint line may be present on palpation. 
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Pain Mechanisms in Osteoarthritis 
Pain, The main presenting symptom of osteoarthritis, is presumed 
to arise from a combination of mechanisms, Including the following: 
 
• Osteophytic periosteal elevation  
 
• Vascular congestion of subchondral bone, leading to 
increased  
          intraosseous pressure  
 
• Synovitis with activation of synovial membrane nociceptors 
 
• Fatigue in muscles that cross the joint 
 
• Overall joint contracture  
 
• joint effusion and stretching of the joint capsule  
 
• torn menisci 
 
• inflammation of periarticular bursae  
 
• periarticular muscle spasm  
 
• psychological factors  
 
• crepitus (a rough or crunchy sensation) 
 
•  central pain sensitization 
 
• Effusions when present are usually without signs of 
inflammation. 
• There can be popliteal bursa enlargement. - Baker’s cyst. 
• Pain over anserine bursa or greater trochanter such in OA due to 
altered biomechanics.52 
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• Soft tissue symptoms may be responding to steroid injection 
relieving pain. 
• Malalignment, usually varus deformity  is seen in severe disease 
but also seen in mild or early disease 
• Varus thrust when clinically appreciated is risk factor for OA 
disease progression.53 
• Severe disease may have flexion deformity and joint instability 
• Quadriceps weakness is early modifiable risk factor for OA 
progression especially in women54,55; In late stages Quadriceps  
atrophy can occur 
• Alteration in proprioception and vibration sense have been 
demonstrated 
• Patellofemoral OA contribute to pain and disability at knee56; 
pain is during ascending or descending stairs located anteriorly 
    
POLYARTICULAR OSTEOARTHRITIS. 
• Long back it has been recognised OA can occur simultaneously 
in multiple joint sites.57 
• Polyarticular  osteoarthritis also called as general  osteoarthritis 
(GOA).  
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• Kellgren and Moore gave the first clinical description of GOA, 
involving heberden’s nodes and the CMC joints, with the spine, 
knees, hips, and feet involved in descending frequency. 
• Newer definition for GOA is more than three or five joint sites 
affected58 multiple hand joint involvement, nodal hand OA 
with other joint involvement59, or summed scores of OA across 
multiple joints. 
• Its important to recognise a patient with single joint 
involvement is likely to have involvement of other joints. 
 
DIAGNOSTIC TESTING 
• Diagnosis of OA is a clinical one, lab testing is rarely required 
• Radiographs usually not required 
• Purpose of additional tests is primarily to rule out potentially 
treatable other metabolic and inflammatory arthropathies. 
 
LAB TESTING 
• CBC, Blood glucose, serum creatinine, LFT  Before initiation 
of pharmacological therapy 
• Rheumatoid factor, thyroid function test may rarely be required 
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SYNOVIAL FLUID 
• Synovial fluid is usually normal or mildly inflammatory. It 
appears clear and colorless or mild yellow 
 
• Leukocyte count less than or equal to 2000cells per mm360 
 
• Fluid is obtained while giving steroid injection. 
 
• Diagnostic aspiration will be done in cases of effusion. 
 
• Coexisting CPPD crystals can be identified. 
 
MOLECULAR BIOMARKER 
• Urinary c telopeptide fragments of type II collagen U CTX II is 
associated with occurrence and progression of radiographic 
OA.61 
 
• Biomarkers in serum, urine or synovium currently used in 
research. 
 
IMAGING: 
• Conventional radiography is inexpensive and widely available, 
used to confirm the diagnosis and exclude other conditions. 
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• X-ray in OA show osteophytes, joint space narrowing, 
osteosclerosis and subchondral bone cysts. 
 
• Kellgren-lawrence grading system commonly used for research 
purpose range from 0 (no osteophytes; no joint space 
narrowing) to 4 (severe joint space narrowing with subchondral 
sclerosis). 
 
• K-L grade 2 is usually considered diagnosis of OA.  
 
• K-L grading is much less helpful in OA of hip. 
 
• Osteoarthritis Research Society International grading system 
(OARSI) view osteophytes and joint space narrowing separately 
and assign separate scores62. 
 
• Imaging of knees should involve both knee joint and in weight 
bearing state. 
 
• Lateral, posteroanterior or sunrise views may be necessary. 
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KELLGREN AND LAWRENCE SYSTEM CLASSIFICATION 
OF OA KNEE 
KL system is a method is a classifying the severity of knee OA 
using five grades: 
• Grade 0 :  no radiographic features of OA present  
• Grade 1 :  doubtful joint space narrowing (JSN) and  
   possible osteophytic lipping. 
• Grade 2 :  definite osteophytes  and possible JSN on  
   anteroposterior weight –bearing radiograph  
• Grade 3 :  multiple osteophytes, define JSN, Sclerosis ,  
   possible bony deformity  
• Grade 4 : large osteophytes, marked JSN, severe sclerosis  
   and definitely bony deformity. 
KL Grade 2                                KL Grade 3 
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KL Grade 4 
 
ADVANCED IMAGING: (MRI) 
• MRI is primarily used for research purpose in OA Knee. 
 
• MRI can be useful in early stages of OA where conventional 
radiographs findings are inapparent. 
 
• MRI useful in excluding avascular necrosis, stress fractures, 
occult fractures, infections and inflammatory conditions.  
 
• Bone marrow lesions of knee MRI, correlate with pain, 
meniscal lesions, bone attrition and progressive cartilage 
damage.63,64,65 
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Subchondral bone marrow lesions in MRI of OA Knee 
USG 
USG is being used in detecting small effusion identifying early 
cartilage changes, differentiates inflammatory and non-inflammatory 
arthropathies. 
USG can be used for accurate aspiration and placement of intra-
articular injection66, 67, 68, 69. 
MORTALITY IN OA 
Mortality is increased in OA patient compare to General 
population. 
Increasing number of joint involvement causes more mortality. 
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Co morbid condition and physical inactivity also contribute to 
increased mortality. 
PERFORMANCE MEASURES. 
Determination of walking speed time to stand from a chair five 
times shown to correlate with severity of OA70,71 
Other functional index (HAQ) Stanford Health Assessment 
Questionnaire, WOMAC INDEX    
 
WOMAC SCALE 
Pain Subscale: (0-20) 
            How much pain do you have ... 
               Walking on a flat surface? 
               Going up or down stairs?  
               At night while in bed? 
               Sitting or lying? 
               Standing upright? 
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Stiffness Subscale: (0-8) 
           How severe is your stiffness.... 
               After first waking in the morning? 
               After sitting, lying down, or resting later in the day? 
 
Function Subscale (0-68) 
1. What degree of difficulty do you have with... 
2. Descending stairs? 
3. Ascending stairs? 
4. Rising from sitting? 
5. Standing? 
6. Bending from floor? 
7. Walking on a flat surface? 
8. Getting in or out of a car? 
9. Going shopping? 
10. Putting on socks or stockings? 
11. Lying in bed? 
12. Getting in and out of the bath? 
13. Sitting? 
14. Getting on or of the toilet? 
15. Heavy domestic duties? 
16. Light domestic duties? 
  
For the above symptoms patients are given a likert scale from 0 to 4 
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TIME TO TOTAL JOINT REPLACEMENT  
• Total knee replacement is the “hard end point ” in OA 
• Joint replacement is affected by patient decision, procedure 
availability insurance coverage and co morbid condition. 
 
MANAGEMENT OF OA 
 NON-PHARMACOLOGICAL INTERVENTION 
 Patient education: Patient should understand that nature of OA 
and it is slowly progressive illness not disabling as 
inflammatory arthritis. 
 Arthritis self help programmes 
 Weight loss 
 Exercise 
 Orthotics 
 Modified activities of daily living 
 
WEIGHT LOSS 
 Higher body mass index is associated with increased 
progression of OA knee72. 
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 Valgus and varus deformities associated with obesity worsen 
the disease symptoms by modulating the effect of weight on 
knee. 
 Weight loss and exercise leads to improvement in pain and 
disability in OA of the knee. 
 Reduction in percentage of body fat instead of weight may be 
significant in reducing pain from OA of the knee73 
 Combination of weight loss and exercise is superior either 
alone74. 
TEMPERATURE MODALITIES 
 Topical application of heat or cold can be help in superficial joints 
like knee 
 Acute  injury  responds  to cold application whereas chronic pain, 
most patient prefer warm application 
 Warm applicators-warm soaks or heating pads 
 Individual session should not exceed a temperature of 45.c 0r last 
more than 30mins75. 
 Warmth should not be applied near testicles, and in patients with 
poor vascular supply, neuropathy or cancer. 
 Benefits of warm applications include decreased pain and stiffness, 
relief of muscle spasm and prevention of contractures 
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EXERCISE 
 Quadriceps muscle  weakness is a risk factor  for  OA  and 
quadriceps strengthening exercises can be useful in OA.76,77 
 DYNAMIC AND ISOMETRIC EXERCISE showed equal 
improvement in symptoms and physical functioning.78 
 Supervised fitness walking regimens improve function in patients 
with OA. 
 Aquatic  exercise programs also have advantage79 
 
ORTHOTICS AND BRACINGS 
 Lateral wedged insoles  provide adequate relief to those with medial 
compartment knee OA particularly those with varus deformity 
 Heel lifts can be useful in patient with hip OA. 
 Valgus bracing in patient with medial compartment OA have 
reduced pain and increased level of activity.80 
 
CANE/WALKING AID 
 Appropriate use of walking stick (cane) can be useful. 
 The cane should be used in hand opposite to the affected knee. 
 The appropriate cane size is which produce 20 deg flexion of the 
elbow during use. 
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MODIFIED IN ACTIVITIES OF DAILY LIVING 
 Avoiding stair cases can reduce pain symptoms and prevent joint 
damage. 
 Switching from high impact activities like jogging or tennis to 
lower impact activities like swimming or cycling will reduce stress 
on the knee. 
 Elevation of toilet seats or shower bends  can be helpful in 
reducing OA symptoms 
 Physicians advice can be extremely helpful in reducing helpful in 
modifying  activities  of daily  living 
 
OTHER INTERVENTION 
 TENS 
 ACUPUNCTURE 
 SPA therapy 
 YOGA 
 PULSED ELECTROMAGNETIC FIELDS 
 STATIC MAGNETS 
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PHARMACOLOGIC INTERVENTION 
SYMPTOMATIC PHARMACOLOGICAL THERAPIES 
 
TOPICAL AGENTS 
 Capsaicin, mechanism of action through selective stimulation of 
unmyelinated type C afferent neurons, causing the release of 
substance P.  
 This release reversibly depletes the stores substance P, where is 
a neurotransmitter of peripheral pain sensation.81 
 Topical NSAIDS preparation include  diclofenac and elfenac 
have been found useful  
 Transdermal lidocaine 5% patches are available for 
management of pain. 
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SYSTEMIC AGENTS 
NON-NARCOTIC ANALGESICS 
 Acetaminophen ( paracetomol) can be used for pain relief  at the 
initial systemic treatment. 
 Acetaminophen may have effect in relieving pain, results  are 
inferior to NSAIDS does not have effect on stiffness and 
functional score . 
 It does not have anti inflammatory effects at approved doses.82 
 Simultaneous use of alcohol can lead to liver disease at 
therapeutic levels. 
NSAIDS 
 NSAIDS act through non specific inhibition of cyclo oxygenase 
isoforms 1 and 2.COX-1 expressed in renal and gastrointestinal 
tissues. 
 Major adverse effects of NSAIDS are GI toxicities (gastritis, 
peptic ulcer disease) and renal toxicities i.e., interstitial 
nephritis, prostaglandins inhibition related renal insufficiency. 
 Rofecoxib was withdrawn due to cardiac risks. 
 All NSAIDS and COX-2 inhibitors received black box warning 
due to CVS risk. 
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 Now selective NSAIDS are ibuprofen, naproxen and diclofenac. 
 NSAIDS are analgesic at lower doses but have both analgesic 
and anti-inflammatory effects at higher doses. 
 PPI prostaglandin E2 analogue misoprostol can reduce GI 
adverse effects. 
NARCOTIC ANALGESICS 
 Narcotics should be considered if patient failed to respond to 
other non-pharmacologic and pharmacologic measures 
 Tramadol has suppressive effects of mu receptors used in 
symptom relief of OA. 
 Transdermal fentanyl used in the treatment of moderate to 
severe OA knee patients. 
INTRA ARTICULAR AGENTS 
 Corticosteroids down regulate expression of cell adhesion 
molecules. 
 Corticosteroids injection causes decrease in cell infiltration of 
the synovium. 
 Dose of steroids depends upon the volume of joint involved. 
 Intraarticular injection has short term benefits but long term 
benefits have been not confirmed.83 
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 In general steroids injections are found to be most effective in 
patient with evidence of inflammation, effusion or both. 
 No more than 4 injections per year are given to particular joint. 
 
HYALURONIC ACID DERIVATIVES 
 Synthetic and natural HA derivative can be administrated intra 
articularly.  
 They reduce pain for prolonged periods and improve joint 
mobility.84 
 Mechanisms of action include lubricant effect in short term 
analgesic effect and stimulating effect of synovial lining cells, 
producing normal HA. 
 Greater improvement in pain, decrease in joint space narrowing   
have been demonstrated. 
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NUTRACEUTICALS 
GLUCOSAMINE  
 Urinary glucosamine found to be elevated in both OA and 
rheumatoid arthritis. 
 Supplementation with glucosamine sulfate has been tried orally 
and intramuscularly. 
 Cochrane review of glucosamine therapy analysed 20 studies and 
2570 patients, pain and function improved by 28% and 21% 
respectively. 
 Combination products glucosamine and chondroitin sulfate have 
been studied found to be more efficacious in more severe 
symptomatic patients. 
CHONDROITIN SULFATE 
 Chondroitin sulfate has been used as therapy for hip and knee OA. 
 Mechanism of action unknown 
 One study showed decreased use of NSAIDS. 
 One study evaluated chondroitin sulfate 300 pts enrolled and 
randomized trial to chondroitin sulfate 800mg daily for two years, 
decreased joint space narrowing and functional improvement was 
found in study group. 
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OTHER NUTRACEUTICALS 
• Glucosamine 
• Chondroitin sulfate 
• Ginger extracts 
• Avocado and soy unsaponifiables 
• Cat’s claw 
• Shark cartilage 
• S-adenosyl methionine 
 
 
1) GINGER EXTRACTS: Contains small amount of salicylates.85 
Ginger has inhibitory effects on COX and lipoxygenase  
 
2) Avocado and soy unsaponifiable residue contains oils in ratio 1: 2; 
ASU has inhibitory effects of IL-1β and decreased production of 
IL-6, IL-8 and MMPS 
 
3) S-adenosyl methionine has tried for OA remedy, but evidence is 
insufficient to recommend its use. 
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POTENTIAL STRUCTURE AND DISEASE MODIFYING DRUGS 
IN OA 
 Tetracyclines 
 Metalloproteinase or collagenase inhibitors 
 Glucosamine  
 Diacerin  
 Growth factors and cytokine IL-1 Receptor antagonist 
 Chondrocyte and stem cell transplantation 
NEW APPROACH FOR OSTEOARTHRITIS 
PLATELET RICH PLASMA INJECTION: 
 Platelets and plasma portion of blood contain factors that are useful 
for cell recruitment, multiplication and specialisation that are required for 
healing. 
 PRP is obtained from patient own blood where the blood sample is 
centrifuged and platelet rich plasma is separated which is injected into 
affected joint with ultrasound guidance. 
 Patient after PRP injection should avoid exercise for a short period 
of time then he can start a rehabilitation exercise program. 
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 In one prospective study of 22 patients, there was important in pain 
as with improvement in WOMAC pain scores and improvement in joint 
stiffness. 
 In one small study PRP treatment was shown to be more effective 
than hyaluronic acid treatment. 
OTHER USES OF PRP: 
• Lateral epicondylitis –Tennis Elbow. 
• Achilles tendon injuries  
• Rotator cuff tears. 
• Medial collateral ligament injuries. 
SURGICAL INTERVENTION    
 Osteotomies are effective pain relieving intervention and can delay 
need for joint replacement surgery in some patient particularly young 
patients. 
• Joint replacement surgery has provided pain relief and 
restoring function. 
 
• Indications for surgery include pain refractory to medical 
management and other measures along with serious impairment 
of patient daily life. 
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• Infections are rare but do occur. 
 
• Joint replacement has life span of 10-15 years revision surgery 
may be necessary. 
 
• Loose body removal and stabilisation of joints are other 
indication for surgery.  
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ALGORITHM FOR THE MANAGEMENT OF OSTEOARTHRITIS 
Diagnosis of  OA  
Patient education psychosocial 
issue? Is patient taking 
nutraceuticals? 
Signification inflammatory 
component? (Clinical 
assessmentof 
severity/inflammation) 
Nonpharmacologic 
modalities Weight loss 
Exrcise temperature 
modalities 
Consider topical agent 
capsaicin 
ia s f  
t ti  syc s ci l 
 i
trace ticals? 
ficatio  infla t
component? (Clinical assessment 
of severity/inflammation) Noninflammatory  
Try  acetaminophen 
Inflammatory 
If single joint involved, consider 
corticosteroid infiltration 
Try NSAID (or 
COX – 2 ), assess 
for GI and 
cardiovascular  risk 
and add cardio – or 
gastro – protective 
measures as  needed 
Consider narcotic analgesics 
if needed for pain relief  
Surgical options 
Consider corticosteroid or 
hyaluroic acid injection if 
suboptimal response to oral 
If suboptimal responce, try 
NSAID (os COX-2 ) , assess 
for GI and cardiovascular risk, 
and add cardio-or 
gastroprotective measures as 
needed 
Surgical 
options 
o side  
l i  i  i j ti  i  
subopti al response to oral 
therapies. Consider narcotic 
analgesics if 
needed for pain 
relief 
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Elevated High Sensitivity C-Reactivity Protein in Osteoarthritis  
• C- reactive protein (CRP) commonly used to differentiate systemic 
inflammatory disorder i.e., rheumatoid arthritis from OA. 
•  With recent development of high sensitivity CRP assays, CRP 
levels lower than traditional assays can be detected. 
• If there is inflammatory component hsCRP can be elevated 
modestly. 
• In rheumatoid arthritis hsCRP level is more than 15 mg/L, but in 
OA it ranges from 3 to 8 mg/L, which is more than the normal 
population. 
• Measuring hsCRP in OA patients may be helpful in detecting 
patient with local inflammation. 
• It has been found that elevation in hsCRP can lead to radiographic 
progression. 
• Elevation in hsCRP may also correlate with clinical severity. 
OTHER CAUSES OF hsCRP ELEVATION  
• Recurrent coronary events. 
• COPD. 
• Rheumatoid arthritis. 
• Asthma. 
• SLE. 
• Diabetes mellitus. 
• Smoking. 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
SELECTION OF VOLUNTEERS:  
          On patient found to have clinical evidence of osteoarthritis of knee 
are selected and subjected to cross sectional study. They are subjected to 
detailed history, clinical examination, and radiographic evaluation of 
knee along with high sensitive C - reactive protein. Then it is planned to 
assess the correlation if any exist between clinical symptoms, radiological 
findings and hsCRP levels. 
STUDY CENTRE: 
          Department of Rheumatology, Madras Medical College and Rajiv 
Gandhi government General Hospital, Chennai. 
DURATION OF THE STUDY  
          6 Months  
STUDY DESIGN  
Observational study 
SAMPLE SIZE  
60 patients  
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DATA COLLECTION AND METHODS  
          Patients have their history taken according to a questionnaire and 
subjected to clinical examination and investigations. 
PRODUCT / PROCEDURE / INVESTIGATION DETAILS  
          X-ray knee, hsCRP levels. 
INCLUSION CRITERIA 
• Idiopathic osteoarthritis  
• Patient with evidence of clinical osteoarthritis  
• Patient aged 40 Yrs and above. 
EXCLUSION CRITERIA  
• Patients with inflammatory rheumatologic disorders RA, SLE, 
crystal arthropathies, Reactive arthritis. 
• Cardiovascular disease,  
• COPD,  
• Ulcerative colitis. 
• Chronic liver, Kidney Diseases, 
• Previous history of local intraarticular steroid injection.  
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STATISTICAL METHODS  
The statistical analysis is done  
SPONSORSHIP  
          No  
CONFLICT OF INTEREST  
None. 
 
  
  
 
OBSERVATION  
AND  
RESULTS 
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OBSERVATION AND RESULTS 
 
          In our study 60 patients found to have osteoarthritis of knee were 
enrolled as participants. Osteoarthritis patients are diagnosed by history 
and clinical examination. Our study was conducted between April 2015 
and September 2015. Aims of the study and study design were explained 
and institutional ethics clearance obtained. 
 
          Osteoarthritis patient enrolled and the purpose of study explained 
to the participants. After the informed consent of the participants detailed 
history and clinical examination were done. Patients who were satisfying 
ACR criteria for osteoarthritis of knee were considered for study. Patients 
with evidence of inflammatory arthritis were excluded, so also there with 
secondary mellitus, hypertensions, chronic liver disease, chronic kidney 
disease were excluded from the study because these factors may interfere 
with our study outcome. 
 
          Symptoms of the patients such as pain, stiffness, swelling and 
disability were enquired. Pain was graded by visual analog scale (VAS) 
graded from 0 to 10 cm. (No pain on the left side of scale to extreme pain 
on right). 
 
64 
 
          All the patients were examined clinically and their body mass index 
calculated, examined for effusion and tenderness and joint deformity. 
 
          X-Ray of both knee joints taken in standing posture, grading of X-
Ray changes done by Kellgren and Lawrence system which is from 0 to 
changes done by Kellgren and Lawrence system which is from 0 to 4. All 
our patients were more than K-L grade 2. 
 
          Blood sample 5ml collected from each patient and centrifuged to 
collect the plasma and stored in frozen state. After collecting all samples 
hsCRP levels estimated by ELISA technique after making adequate 
dilution. 
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AGE DISTRIBUTION CHART 
 
 
(Standard deviation 6.31mean 61.45) 
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STANDARD AGE DISTRIBUTION IN OUR PATIENT 
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Age group Total Percentage 
41-45 1 1.6 
46-50 2 3.3 
51-55 10 16.7 
56-60 14 23.3 
61-65 20 33.4 
66-70 8 13.4 
71-75 3 5 
76-80 2 3.3 
 
 
 
1. From our study age distribution chart shows as age advances 
prevalence of osteoarthritis increases. 
2. Mean age of our study group is 61.45 yrs, with minimum 45 yrs and 
max 78 yrs. 
3. Standard deviation of 6.31.  
4. Maximum incidence was in the age group 61-65 yrs. 
5. Irrespective of age group females are affected more than males. 
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SEX DISTRIBUTION 
 
 
 
 
1. Out of 60 patients studied 25 are male and 35 are female. 
2. There is more prevalence of osteoarthritis in female patients in our 
study. 
 
  
42%
58%
Male Female
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BMI DISTRIBUTION 
Gender Number Percentage 
Male 25 42 
Female 35 58 
 
In our study BMI ranges from 18.49 to 29.43 around 
73.36% of our patient are the category of overweight and 
obesity. 
 Average BMI of males in our group is 23.97, 
Average BMI of females in our group is 24.40. 
 In our study none of the patient had BMI more than 30. 
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Standard Distribution of hsCRP in our patient 
 
• Mean hsCRP level in our patient 4.0 mg/dl 
 
• hsCRP level in our patient ranges from 2.0mg/dl to 7.0 mg/dl,  
 
• hsCRP is more than that of healthy general population. (>1.1 
mg/dl)  
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PAIN DISTRIBUTION IN OUR PATIENT 
Pain Score No. Of Patient 
VAS 3 3 
VAS 4 10 
VAS 5 7 
VAS 6 26 
VAS 7 14 
VAS 8 0 
 
• Most of our patient symptomatic with pain range from mild 
moderate and sever. 
• Average pain score of our patient is 5.6 in VAS Scale.   
 
X-ray – KL grading distribution 
X RAY GRADE KL No. Of patients 
GRADE 2 20 
GRADE 3 26 
GRADE 4 14 
 
• Many of our patients belong to grade 3KL Grading. 
• Pain severity does not match with KL Grading. 
• Deformity is present in Grade 3 and Grade 4 patient.  
 
 ANALYSIS OF
SCATTER GRAPH BETWEEN PAIN
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 hsCRP LEVELS AND PAIN SCALE
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Data Summary 
 Samples 
VAS 3 VAS 4 VAS 5 VAS 6 VAS 7 Total 
N 3 10 7 26 14 60 
ƩX  6.3 24.2 22.3 112.1 76.1 241 
Mean 2.1 2.42 3.1857 4.3115 5.4357 4.0167 
ΣX2 13.25 59.92 75.41 498.89 428.79 1076.26 
Variance 0.01 0.1507 0.7281 0.6227 1.164 1.8346 
Std. Dev. 0.1 0.3882 0.8533 0.7891 1.0789 1.3545 
Std. Err. 0.0577 0.1227 0.3225 0.1548 0.2883 0.1749 
 
X = hsCRP 
Standard weighted – means analysis 
ANOVA Summary Independent Samples k=5 
Source SS df MS F P 
Treatment 
[between 
groups] 
71.8001 4 17.95 27.09 <.0001 
Error 36.4433 55 0.6626  
Ss/BI    
Total 108.2434 59 
 
 
 
  
ANALYSIS OF hsCRP AND KL GRADING 
 
Data Summary 
 
KL Grade 2
N 
 ΣX 
Mean 
 ΣX2 295.39
Variance  1.3304
Std. Dev. 1.1534
Std. Err. 0.2579
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Samples 
 KL Grade 3 KL Grade 4
20 26 14 
73.5 115.9 51.6 
3.675 4.4577 3.6857 
 555.61 225.26 
 1.5585 2.6982 
 1.2484 1.6426 
 0.2448 0.439 
4
Grade 3 Grade 4
hs CRP
Grade 3 Grade 4
 Total 
60 
241 
4.0167 
1076.26 
1.8346 
1.3545 
0.1749 
4
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Standard weighted- means analysis 
ANOVA  SUMMARY Independent Samples k=3 
Source SS Df MS F P 
Treatment 
[between  
groups] 
8.9252 2 4.4626 2.56 0.086166 
Error 99.3181 57 1.7424  
Ss/BIs    
Total 108.2433 59 
  
 
ANALYSIS OF BMI AND hsCRP 
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PEARSONS CORRELATION METHOD 
Result Details & calculation 
 
X values 
 Σ = 1453.19 
Mean  = 24.22 
 Σ(X-Mx)2 = SSx = 478.253 
 
Y values 
 Σ = 241 
Mean = 4.017 
 Σ(Y – My)2 = ssy = 108.243 
 
X and Y combined 
N = 60 
 Σ(X-Mx)Y-My) = 156.146 
 
R Calculation 
r =  Σ((X-My)(Y-Mx)) / 
√((SSx)(SSy)) 
 
r = 156.146 / √((478.253)(108.243)) 
= 0.6863 
 
Meta Numerics (cross-check) 
r = 0.6863 
 
Key 
 
X:  BMI Values 
Y : hsCRP Values 
Mx: Mean of  BMI Values 
My: Mean of  hsCRP Values 
X - Mx & Y – My:  Deviation 
Scores 
(X – Mx)2 & (Y – My)2: Deviation 
Squared 
(X – Mx)(Y –My): Product of 
Deviation scores 
 
The value of R is 0.6863. This is a moderate positive correlation, 
which means there is a tendency for high X (BMI ) variable scores go 
with high Y (hsCRP) variable scores (and vice versa). 
 
 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
• When compared to study by A.D pearle, C.R.Scanzello et al. our 
patient had similar sex distribution with increased female 
prevalence  
• Mean age in our patient was 61.45 years compared to 64.2 years, 
by A.D pearle, C.R.Scanzello et al. 
• Mean BMI in our study 24.22 compared to 28.50 in their study 
showing that our patient had osteoarthritis with lower BMI levels. 
• K.L.grade severity is comparable to that of study by A.D pearle, 
C.R.Scanzello et al. median K.L grade 3. 
• Mean hsCRP levels 4.0 mg/dl in our study compared to 2.4 mg/dl 
studied by T.Sturmer, H.Brunner et al. 
• Comparing hsCRP and pain scales both our study by T.Sturmer, 
H.Brunner et al. showed statistically significant association 
between hsCRP and pain symptoms. 
• Comparing hsCRP and K.L grading our study had no statistically 
significant correlation with hsCRP levels as studied by T.Sturmer, 
H.Brunner et al. 
• BMI had mild correlation with hsCRP levels as compared to study 
by A.D.Pearle et al. 
 
  
 
 
CONCLUSION 
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CONCLUSION 
          In our studyof hscrp levels in osteoarthritis patients the following 
conclusions are 
• Osteoarthritis is more prevalent in females. 
• hscrp levels are modestly elevated in many patients particularly 
those with local symptoms . 
• hscrp levels rise with increasing pain scores. 
• hscrp levels do not correlate with x-ray grading . 
• hscrp levels have minimal correlation with body mass index. 
• patients with high levels of hscrp are likely to progress to advance 
disease. 
 
  
  
 
 
LIMITATIONS 
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LIMITATION OF STUDY 
• Our study size is small for comarision of  for the large population. 
 
• Extrems of BMI were not taken into account. 
 
• Our patients are symtamatic hence hsCRP levels in A-symptomatic 
patient or not included in our study.  
 
• Our study did not have controles subject, hsCRP control level is 
taken general population. 
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ANNEXURES 
  
ABBREVIATIONS 
 
HsCRP  - high sensitive Creactive protein 
K-L GRADE - Kellgren and Lawrence Grading 
I-L     - Interleukin 
ACR   - American College of Rheumatology 
COMP  - Cartilage Oligomeric Matrix Protein 
VAS   - Visual Analog Scale 
OARSI  - Osteoarthritis Association Research Society  
    International 
BMI   - Body Mass Index 
MMP   - Matrix MetalloProteinase 
CPPD  - Calcium PyroPhosphate Dehydarate  
HA   - Hyaluronic Acid 
CTX-II  - C-Terminal telopeptide of type 2 collagen 
WOMAC  - Western Ontario MacMaster Arthritis Index 
COX   - Cyclo-oxygenase 
NSAIDS  - Nonsteroidal Anti-inflammatory drugs 
UA   - Uric ACID 
PROFORMA  
Name : 
Age/Sex : Weight : 
IP No : Height  : 
Patient ID No : Diagnosis : 
  Duration : 
Patient characteristics Medications 
❏ Smoking ❏ NSAIDS 
❏ Alcoholism ❏ Statins 
❏ Diabetes  
❏ Systemic hypertension ❏ Others  
❏ Coronary events 
 
 Symptoms    
❏ Pain  
❏ Stiffness   
❏ Physical function   
❏ Restriction of  activities of daily living   
 
Clinical examination 
BMI  Knee  
 Effusion    
 Warmth    
 Deformity    
 Crepitus    
 Range of movements    
 Joint line tenderness    
 Synovial thickening    
Serum hsCRP level  
<3 3-8 >8  
   
 
  


 
   
   
  
 
 
 
 
MASTER CHART 
 
MASTER CHART 
S.No Age Sex Height Weight BMI 
Pain 
VAS Swelling Deformity 
KL 
Grade 
hsCRP 
level 
1 62 F 150 50 22.22 6 YES No 3 3.4 
2 55 M 170 62 21.45 7 YES No 3 3.9 
3 54 F 154 60 25.3 6 No No 2 2.6 
4 60 M 160 58 22.66 7 No No 3 3.5 
5 65 F 152 52 22.51 5 No Yes 3 2.8 
6 54 M 160 62 24.22 6 YES No 2 4.3 
7 52 F 152 45 19.48 5 No No 2 2.6 
8 58 M 170 65 22.49 6 YES No 2 3.3 
9 75 F 160 55 21.48 7 YES Yes 3 5.1 
10 65 M 167 65 23.31 7 YES No 3 4.6 
11 67 F 156 55 22.6 7 YES No 2 4.4 
12 59 M 168 66 23.38 6 YES No 3 4.8 
13 65 F 155 65 27.06 7 YES No 3 6.2 
14 56 M 160 65 25.39 6 No No 2 4.6 
15 54 F 154 60 25.3 6 No No 2 3.9 
16 60 M 160 67 26.17 4 No Yes 3 2.4 
17 57 M 165 62 22.77 6 YES No 2 3.3 
18 65 M 160 70 27.34 7 YES No 2 6.8 
19 66 F 155 65 27.06 7 YES Yes 4 7 
20 51 M 162 59 22.48 4 No No 2 2.2 
21 49 F 158 68 27.24 6 YES Yes 3 6.4 
22 78 M 160 70 27.34 6 YES Yes 4 5.8 
23 60 F 155 66 27.47 6 YES No 3 5.1 
24 76 M 164 58 21.56 3 No Yes 4 2.1 
25 60 F 146 52 24.39 5 YES No 3 4.4 
26 61 M 163 54 20.32 6 YES No 2 4.6 
27 63 F 152 60 25.97 6 YES No 2 4.1 
28 62 M 163 60 22.58 5 No No 2 2.8 
29 63 F 160 64 25 6 No No 3 3.8 
30 54 M 160 65 25.39 5 No No 2 3.4 
 
MASTER CHART -2 
S.No Age Sex Height Weight BMI 
Pain 
VAS 
Swell 
ing 
Defor 
mity 
KL 
Grade 
hsCRP 
level 
31 58 F 150 60 26.67 6 YES No 2 4.6 
32 62 M 163 60 22.58 6 YES Yes 4 3.8 
33 63 F 162 65 24.77 4 No Yes 4 2.2 
34 66 M 160 75 29.30 6 YES Yes 4 4.3 
35 65 F 150 56 24.89 6 YES No 2 4.6 
36 65 M 158 69 27.64 7 YES No 3 5.2 
37 57 F 160 70 27.34 6 YES Yes 3 4.8 
38 70 M 162 73 27.82 7 YES Yes 4 5.7 
39 62 F 152 68 29.43 7 YES Yes 3 5.9 
40 56 M 165 56 20.57 5 No No 2 2.1 
41 55 F 150 65 28.89 6 YES No 3 4.9 
42 70 M 168 62 21.97 4 No Yes 4 2.3 
43 56 F 158 68 27.24 5 YES No 2 4.2 
44 45 F 150 45 20.00 4 No No 2 2.7 
45 56 F 155 65 27.06 6 YES No 3 3.9 
46 64 F 160 50 19.53 3 No Yes 4 2 
47 64 F 150 48 21.33 4 No No 3 2.1 
48 65 F 150 65 28.89 6 YES Yes 4 4.3 
49 71 F 150 48 21.33 4 No Yes 4 3.4 
50 65 F 156 69 28.35 7 YES No 3 6.1 
51 47 M 168 64 22.68 6 YES No 3 3.9 
52 58 F 150 55 24.44 6 YES No 3 4.7 
53 67 F 156 60 24.65 7 YES No 3 5.1 
54 71 F 160 56 21.88 4 YES Yes 4 2.1 
55 54 F 156 45 18.49 4 No No 2 2.4 
56 68 M 165 59 21.67 6 YES No 3 3.9 
57 63 F 160 62 24.22 6 YES Yes 4 4.4 
58 55 F 165 56 20.57 4 No No 3 2.4 
59 65 F 167 58 20.80 3 No Yes 4 2.2 
60 66 M 169 75 26.26 7 YES Yes 3 6.6 
 
   
  
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
  
